The use of Ranibizumab (Lucentis ®) for the treatment of corneal neovascularisation - Management and control of corneal neovascularisation using Lucentis
- Conditions
- Corneal neovessels
- Registration Number
- EUCTR2010-018673-37-GB
- Lead Sponsor
- niversity of Nottingham
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- Not specified
- Target Recruitment
- 6
Patients with all the below criteria:
- Patients over the age of 18
- With corneal neovascularisation non responsive or non tolerant to conventional steroid therapy
- And capable of consenting
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
- Patients under 18 years of age
- Patients unable to provide informed consent
- Patients who are needle phobic
- Patients refusing consent
- Pregnant women or women aiming for conception
- Patients with communication difficulties
- Patients with hypersensitivity to the active substance or to any of the excipients.
- Patients with active or suspected ocular or periocular infections.
- Patients with active severe intraocular inflammation.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To assess the use of the drug in the treatment of active corneal new blood vessels.;<br> Secondary Objective: To determine whether established corneal vessels too would be influenced to a limited extent with lucentis and whether there is any gain in visual acuity following ‘regression’ of corneal new vessels.<br> (regressed vessels remain as fine white lines ‘ghost vessels’ that no longer carry blood).<br> ;Primary end point(s): Decreased corneal neovascularisation
- Secondary Outcome Measures
Name Time Method